Nodular Regenerative Hyperplasia in Patients Undergoing Liver Resection for Colorectal Metastases After Chemotherapy: Risk Factors, Preoperative Assessment and Clinical Impact

Annals of Surgical Oncology

Volumn 22, Issue 13, 2015, Pages 4149-4157

  Viganò, Luca ^a,b   Rubbia Brandt, Laura ^c   De Rosa, Giovanni ^b   Majno, Pietro ^c   Langella, Serena ^b   Toso, Christian ^c   Mentha, Gilles ^c   Capussotti, Lorenzo ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; BILE LEAKAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURGERY; CHEMOTHERAPY RELATED LIVER INJURY; COLORECTAL CANCER; COLORECTAL METASTASIS; FEMALE; GOMORI STAINING; HEMATOLOGICAL PARAMETERS; HEMORRHAGIC CENTRILOBULAR NECROSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER FAILURE; LIVER INJURY; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NODULAR HYPERPLASIA; NODULAR REGENERATIVE HYPERPLASIA; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PERISINUSOIDAL FIBROSIS; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PURPURA; RISK FACTOR; SCORING SYSTEM; SINUSOIDAL DILATATION; STEATOSIS; SURGICAL RISK; THROMBOCYTE COUNT; WANLESS SCORE; WEDGE RESECTION; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLORECTAL NEOPLASMS; FOCAL NODULAR HYPERPLASIA; FOLLOW UP; LIVER NEOPLASMS; LIVER REGENERATION; MULTIMODALITY CANCER THERAPY; PREOPERATIVE CARE; PROGNOSIS; SECONDARY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOCAL NODULAR HYPERPLASIA; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; RISK FACTORS;

EID: 84947127896     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4533-0     Document Type: Article

References (35)

1. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003;138:1198–206.
2. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406.
3. Andres A, Toso C, Moldovan B, et al. Complications of elective liver resections in a center with low mortality: a simple score to predict morbidity. Arch Surg. 2011;146(11):1246–52.
4. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11(8):1057–77.
5. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.
6. Viganò L, Russolillo N, Ferrero A, Langella S, Sperti E, Capussotti L. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. Ann Surg Oncol. 2012;19(6):2035–44.
7. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72.
8. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.
9. de Meijer VE, Kalish BT, Puder M, Ijzermans JNM. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg. 2010;97(9):1331–39.
10. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–39.
11. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.
12. Wicherts DA, de Haas RJ, Sebagh M, et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol. 2011;18(3):659–69.
13. Viganò L, Ravarino N, Ferrero A, Motta M, Torchio B, Capussotti L. Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapy-associated liver injuries. Arch Surg. 2012;147(12):1085–91.
14. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24(31):4983–90.
15. Hubert C, Sempoux C, Horsmans Y, et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int. 2007;27(7):938–43.
16. Schwarz L, Faitot F, Soubrane O, Scatton O. Splenic artery ligation for severe oxaliplatin induced portal hypertension: A way to improve postoperative course and allow adjuvant chemotherapy for colorectal liver metastases. Eur J Surg Oncol.2014;40(6):787–88.
17. Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol. 2004;75(4):225–30.
18. Sarin SK, Khanna R. Non-cirrhotic portal hypertension. Clin Liver Dis. 2014;18(2):451–76.
19. Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–40.
20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.
21. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11(5):787–97.
22. Viganò L, Langella S, Ferrero A, Russolillo N, Sperti E, Capussotti L. Colorectal cancer with synchronous resectable liver metastases: monocentric management in a hepatobiliary referral center improves survival outcomes. Ann Surg Oncol. 2013;20(3):938–45.
23. Mentha G, Roth AD, Terraz S, et al. ‘Liver first’ approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg. 2008;25(6):430–35.
24. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
25. Capussotti L, Viganò L, Giuliante F, Ferrero A, Giovannini I, Nuzzo G. Liver dysfunction and sepsis determine operative mortality after liver resection. Br J Surg. 2009;96(1):88–94.
26. Capussotti L, Ferrero A, Viganò L, Sgotto E, Muratore A, Polastri R. Bile leakage and liver resection: Where is the risk? Arch Surg. 2006;141(7):690–94.
27. Soubrane O, Brouquet A, Zalinski S, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251(3):454–60.
28. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110(12):2761–7.
29. Morris-Stiff G, White AD, Gomez D, et al. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. Eur J Surg Oncol. 2014;40(8):1016–20.
30. Aloia TA, Vauthey JN. Management of colorectal liver metastases: past, present, and future. Updates Surg. 2011;63(1):1–3.
31. Snover DC, Weisdorf S, Bloomer J, McGlave P, Weisdorf D. Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology. 1989;9(3):443–8.
32. Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D. Nodular regenerative hyperplasia of the liver associated with azathioprine therapy. Gastroenterol Clin Biol. 1991;15(12):968–73.
33. Washington K, Lane KL, Meyers WC. Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol. 1993;17(11):1151–8.
34. Mentha G, Terraz S, Andres A, Toso C, Rubbia-Brandt L, Majno P. Operative management of colorectal liver metastases. Semin Liver Dis Management of colorectal liver metastases: past, present, and future 2013;33(3):262–72.
35. Allard MA, Adam R, Bucur PO, et al. Posthepatectomy portal vein pressure predicts liver failure and mortality after major liver resection on noncirrhotic liver. Ann Surg. 2013;258(5):822–9.